Logo image
Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline
Journal article   Peer reviewed

Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline

Alice Chen, Kenneth P. Smith, Betsy A. Whitfield, Paola C. Zucchi, Todd M. Lasco, Tiffany E. Bias, James E. Kirby and Elizabeth B. Hirsch
Diagnostic microbiology and infectious disease, v 88(4), pp 365-367
01 Aug 2017
PMID: 28535946

Abstract

Infectious Diseases Life Sciences & Biomedicine Microbiology Science & Technology
We examined the in vitro activity of minocycline against 103 Klebsiella pneumoniae carbapenemase (KPC)producing Enterobacteriaceae isolates and found approximately half had susceptible (26%) or intermediate (26%) MICs. For a subset of 35 isolates, susceptibility was highest to tigecycline (71% FDA vs. 20% EUCAST) followed by minocycline (14%) and then doxycycline (6%). (C) 2017 Elsevier Inc. All rights reserved.

Metrics

5 Record Views
10 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Infectious Diseases
Microbiology
Logo image